What Analysts Are Saying About Edwards Lifesciences Stock
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) has received diverse analyst ratings over the past three months, with a recent positive shift in sentiment. Analysts have provided a range of 12-month price targets, with an average target of $97.4, a high of $107.00, and a low of $85.00. The company's financials show strong net margins, ROE, and ROA, although its revenue growth lags behind industry peers.
May 30, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences has seen a positive shift in analyst sentiment, with recent ratings showing increased price targets. The company's strong financial metrics, including net margins and ROE, are highlighted, although its revenue growth is below industry average.
The positive shift in analyst sentiment, with multiple analysts raising their price targets, suggests a bullish outlook for Edwards Lifesciences. The company's strong financial metrics further support this positive sentiment, although the lower revenue growth compared to peers may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100